|
|
Opgen Inc
OPGN's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Opgen Inc 's sales fell
in the third quarter of 2024 from the same quarter a year ago.
Medical Laboratories industry recorded
growth of revenues by 6.47 %
Opgen Inc realized net income compared to net loss a year ago in third quarter of 2024
• More on OPGN's Growth
|
|
Opgen Inc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 28.35 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
-0 |
|
PE TTM
|
|
Company's Price to Sales ratio is at 25.77.
Medical Laboratories industry's Price to Sales ratio is at 2.26.
• More on OPGN's Valuation
|
|
|
|
|
Opgen Inc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 28.35 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
-0 |
|
PE TTM
|
|
Company's Price to Sales ratio is at 25.77.
Medical Laboratories industry's Price to Sales ratio is at 2.26.
Opgen Inc Price to Book Ratio is at 10.92 lower than Industry Avg. of 329.63. and higher than S&P 500 Avg. of 0.01
• More on OPGN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
